Post by jamesjohnson12 on Aug 7, 2020 20:28:13 GMT
Anybody following this stock? Just had a substantial sell off today after a pretty conference call. I wanted to bring to everyone's attention because now is a good entry point in my opinion. The stock was pumped by some day traders prior which made it run to the low teens and since the CC didn't have any material update, seems like day traders are fleeing to greener pastures. However, there seems to be a lot to like about this stock.
Have great Phase II data on Duchennes Muscular Distrophy, which they applied for accelerated approval. From my memory, the CC was a little wishy washy and may have implied that they will need a Phase III before approval. However, the results here seem very good and DMD has no true effective therapy, is an awful disease, and is still a fairly substantial treatment market. I think investors were looking for clarity that there was a path toward accelerated approval and they did not get it on the CC. In this way, it reminds me a bit of where ATHX is with multi-stem trials.
The company also has 3 Covid plays. Cap 1002 - which is to treat the Cytokine storm. Dosed 7 patients earlier this summer. I believe the 7 patients survived and biomarker data showed improvement after administration of the drug consistently in all individuals. They have submitted for a placebo controlled trial and are waiting for FDA approval to proceed. Pretty big near term catalyst. I am not convinced that this will ultimately be successful, but just the approval of the trial will lead to a healthy pop in my opinion.
The company has done a lot of research on exosomes and have two exosome based vaccine trials underway in animal studies for covid 19. These sound very exciting and represent a platform for new, robust vaccines that can be applicable for many different diseases. I am not technically knowledgeable enough to go into great depth, but it sounded very exciting. Results from the animal studies could be forthcoming soon as well. They mentioned that there are going to be multiple efficacious vaccines, but thought that their exosome platform may end up being very effective compared to others.
Hopefully someone that is technically knowledgeable can opine. This is a small market cap company ($100mm), which the DMD by itself will be worth multiples of that within a year. The Cap 1002 trial on Covid 19 could trigger a near term pop upon approval and the Exosome vaccine platform and research is extremely promising.
I think it is a good time to buy as it is selling off and they have a good cash position ($36mm+ with $12-15mm cash burn per year). I have accumulated over the past month (before the pop and now on the sell off). I am planning on unloading some shares after the covid trial is approved and the subsequent share price pop. This company interests me for the long term as much as any that I have looked at recently.
Have great Phase II data on Duchennes Muscular Distrophy, which they applied for accelerated approval. From my memory, the CC was a little wishy washy and may have implied that they will need a Phase III before approval. However, the results here seem very good and DMD has no true effective therapy, is an awful disease, and is still a fairly substantial treatment market. I think investors were looking for clarity that there was a path toward accelerated approval and they did not get it on the CC. In this way, it reminds me a bit of where ATHX is with multi-stem trials.
The company also has 3 Covid plays. Cap 1002 - which is to treat the Cytokine storm. Dosed 7 patients earlier this summer. I believe the 7 patients survived and biomarker data showed improvement after administration of the drug consistently in all individuals. They have submitted for a placebo controlled trial and are waiting for FDA approval to proceed. Pretty big near term catalyst. I am not convinced that this will ultimately be successful, but just the approval of the trial will lead to a healthy pop in my opinion.
The company has done a lot of research on exosomes and have two exosome based vaccine trials underway in animal studies for covid 19. These sound very exciting and represent a platform for new, robust vaccines that can be applicable for many different diseases. I am not technically knowledgeable enough to go into great depth, but it sounded very exciting. Results from the animal studies could be forthcoming soon as well. They mentioned that there are going to be multiple efficacious vaccines, but thought that their exosome platform may end up being very effective compared to others.
Hopefully someone that is technically knowledgeable can opine. This is a small market cap company ($100mm), which the DMD by itself will be worth multiples of that within a year. The Cap 1002 trial on Covid 19 could trigger a near term pop upon approval and the Exosome vaccine platform and research is extremely promising.
I think it is a good time to buy as it is selling off and they have a good cash position ($36mm+ with $12-15mm cash burn per year). I have accumulated over the past month (before the pop and now on the sell off). I am planning on unloading some shares after the covid trial is approved and the subsequent share price pop. This company interests me for the long term as much as any that I have looked at recently.
